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ABSTRACT
Epithelial to mesenchymal transition (EMT) involves loss of an epithelial 
phenotype and activation of a mesenchymal one. Enhanced expression of genes 
associated with a mesenchymal transition includes ZEB1/2, TWIST, and FOXC1. 
miRNAs are known regulators of gene expression and altered miRNA expression 
is known to enhance EMT in breast cancer. Here we demonstrate that the tumor 
suppressive miRNA family, miR-200, is not expressed in triple negative breast cancer 
(TNBC) cell lines and that miR-200b-3p over-expression represses EMT, which is 
evident through decreased migration and increased CDH1 expression. Despite the loss 
of migratory capacity following re-expression of miR-200b-3p, no subsequent loss 
of the conventional miR-200 family targets and EMT markers ZEB1/2 was observed. 
Next generation RNA-sequencing analysis showed that enhanced expression of pri-
miR-200b lead to ectopic expression of both miR-200b-3p and miR-200b-5p with 
multiple isomiRs expressed for each of these miRNAs. Furthermore, miR-200b-5p 
was expressed in the receptor positive, epithelial breast cancer cell lines but not 
in the TNBC (mesenchymal) cell lines. In addition, a compensatory mechanism for 
miR-200b-3p/200b-5p targeting, where both miRNAs target the RHOGDI pathway 
leading to non-canonical repression of EMT, was demonstrated. Collectively, these 
data are the first to demonstrate dual targeting by miR-200b-3p and miR-200b-5p 
and a previously undescribed role for microRNA processing and strand expression in 
EMT and TNBC, the most aggressive breast cancer subtype.
INTRODUCTION
Breast cancer can be classified into distinct sub-
types, including luminal and basal subtypes, based on 
molecular markers that define their phenotype and predict 
therapeutic response [1]. The triple-negative sub-type is 
characterized by loss of estrogen receptor, progesterone 
receptor, and Her2/Neu, and therefore is not responsive to 
current targeted therapeutics. Triple-negative breast cancer 
(TNBC) is also one of the most aggressive subtypes of 
breast cancer, with a clinically observed higher rate of 
distant metastasis and poor overall survival [1, 2]. TNBC 
can be further subdivided into 6 subtypes based upon 
gene expression profiles, and include basal-like (1 and 2), 
immunomodulatory, mesenchymal, mesenchymal stem-
like, and luminal androgen receptor [3], illustrating 
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the heterogeneity of this subtype. Although molecular 
subtyping has begun to elucidate the signaling events 
regulating this aggressive form of breast cancer, much 
remains to be investigated. RNA based next generation 
deep sequencing for both large and small RNAs allows for 
great depth in investigating differences in gene expression 
profiles for breast cancer subtypes.
miRNA mediated regulation of breast cancer has 
received considerable attention due to evidence of miRNA 
regulation of drug resistance, metastasis, receptor status, 
and the epithelial-to-mesenchymal transition (EMT) [4–6]. 
The expression of the miR-200 family cohort of miRNAs 
is lost in mesenchymal breast cancer subtypes compared 
to epithelial subtypes [7]. This miRNA family exists in 
two clusters: one on chromosome 1 (miR-200b-3p, miR-
200b-5p, miR-200a-3p, miR-200a-5p, and miR-429) and 
the other on chromosome 12 (miR-200c-3p, miR-200c-
5p, miR-141-3p, and miR-141-5p) [8, 9]. Conventionally 
the miR-200 family is a regulator of epithelial–cadherin 
(CDH1) expression through the direct targeting of zinc 
finger E-box-binding homeobox 1 (ZEB1) and 2 (ZEB2) 
[10]. However, canonical signaling of miR-200 family 
and ZEB1/2 demonstrates an inhibitory mechanism where 
ZEB1 and ZEB2 can repress miR-200 family expression 
[11]. Collectively a negative feedback loop has been 
established for the miR-200 family and ZEB1/2 which 
ultimately leads to the regulation of CDH1 and EMT/MET. 
The increased expression of ZEB1/2 leads to the loss of 
miR-200 and CDH1, while the increased expression of 
miR-200 leads to loss of ZEB1/2 and increased CDH1 [11]. 
Although this has been the dogma for miR-200 regulation 
of EMT, recent studies suggest non-canonical mechanisms 
for miR-200 family regulation of EMT independent of 
ZEB1 and ZEB2, as well as miR-200 family as regulators 
of EMT through both canonical and non-canonical ZEB/
miR-200/CDH1 mechanisms and through interactions with 
TGF-β, hedgehog, and RHO signaling pathways [12–14].
Here we demonstrate through next generation 
sequencing analysis miR-200b-3p regulation of EMT in 
the TNBC subtype through inhibition of the RHO signaling 
cascade. Additionally, through the enforced expression of pri-
miR-200b we demonstrate altered processing and enhanced 
expression of miR-200b-5p. Furthermore we demonstrate a 
compensatory mechanism where both miR-200b and miR-
200b-5p target the RHO signaling cascade. These results 
demonstrate a novel mechanism for miR-200 family in the 
regulation of EMT, highlighting the importance of miRNA 
processing and miRNA strand expression in breast cancer.
RESULTS
MiR-200 family is differentially expressed across 
breast cancer cell lines
qPCR analysis of a panel of breast cancer cell 
lines revealed suppressed expression of all miR-200 
family members in cell line models of the TNBC subtype 
(Figure 1A). However, only repression (~100-fold) of 
miR-200b-3p was consistently observed in all TNBC cell 
lines tested. While there has been a clear association of 
miR-200 members in regulation of EMT, cell motility 
and metastasis, the role of miR-200b-3p in this process 
has not been fully established [15, 16]. As a recent report 
using computational modeling of miRNA and mRNA 
expression data from patient samples demonstrated a loss 
of miR-200b-3p expression and activity that specifically 
correlated to the basal breast cancer sub-type [17], we 
chose to further examine the specific effects of miR-200b-
3p on the TNBC sub-type.
miR-200b-3p expression suppresses TNBC cell 
migration and EMT-gene expression
To directly assess the sub-type specific effects 
of miR-200b-3p, the TNBC cell line, MDA-MB-231, 
was transfected with pLEmiR-tRFP-miR-vector or –
pri-miR-200b expression plasmids. Following stable 
selection, expression of mature processed miR-200b-3p 
was confirmed by qPCR. Expression of mature miR-
200b-3p increased 353.5-fold in MDA-MB-231 cells 
(Figure 1B), compared to corresponding vector control 
cell lines.
As previous studies have shown that miR-200 
family regulates the metastatic potential of cancer cells 
[12], we examined the effect of miR-200b expression on 
TNBC cell migration using in vitro transwell migration 
assays, which have been correlated with metastatic 
potential [18]. MDA-MB-231-miR-200b cells showed 
a 50% reduction in migration capacity than their vector 
counterparts (Figure 1C), indicating that miR-200b-3p 
plays a role in migration suppression and in agreement 
with a previous study [19].
The EMT has been recognized as a major player in 
cancer cell migration, invasion, and metastasis [20]. EMT is 
characterized by the loss of epithelial cell markers, namely 
CDH1, enhanced expression of mesenchymal cell markers, 
including neuronal–cadherin (CDH2) and vimentin (VIM), 
and increased expression of CDH1 transcriptional repressors 
such as ZEB1 and ZEB2 [21–24]. The expression of EMT 
markers, including CDH1, CDH2, VIM, ZEB1 and ZEB2, 
is associated with poor prognosis of breast cancer patients 
[25, 26]. As such, regulators of EMT have become attractive 
targets for the development of anti-metastasis therapies. The 
canonical suppression of EMT by miR-200 family members 
occurs through targeting of ZEB1 and 2, direct repressors of 
the epithelial marker, CDH1 [10, 27, 28]. To better assess the 
effects of miR-200b-3p overexpression in the MDA-MB-
231-miR-200b cell line qPCR for CDH1, ZEB1, and ZEB2 
was performed. Results demonstrated a significant increase 
in CDH1 expression in the MDA-MB-231-miR-200b cells 
compared to vector control but expression of ZEB1 and 
ZEB2 remained essentially unchanged (Figure 1D).
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miR-200b expression induces global gene 
expression changes
Due to the lack of ZEB1 and ZEB2 repression in 
MDA-MB-231-miR-200b cell line, we evaluated global 
transcriptome changes invoked through pri-miR-200b 
overexpression using next generation RNA-sequencing of 
the MDA-MB-231-miR-200b versus vector control cells. 
Prior to sequencing, RNA libraries were fractioned by size 
to generate full length and small RNA libraries, which 
were analyzed independently. Gene expression analysis 
of the full length data set revealed expression levels of 
1831 genes that were significantly ( p < 0.05) altered 
following pri-miR-200b overexpression, with 824 genes 
upregulated and 1007 genes downregulated (Figure 2A). 
Some genes associated with EMT were demonstrated to be 
both significantly enhanced and repressed (Supplemental 
Table 1). However, these genes showed only minimal 
changes in expression level. Pathways significantly 
downregulated in the MDA-MB-231-miR-200b cells 
included many pathways associated with cell motility and 
cancer metastasis, such as axonal guidance, chemokine, 
epithelial adherens junction, and actin cytoskeleton 
signaling (Figure 2B). Of particular interest was the down-
regulation of RHO signaling, given the widely known role 
of RHO dysregulation in cancer [29]. On the other hand, 
the most upregulated pathway in the miR-200b stable 
cells was the stabilization and expansion of E-cadherin 
adherens junction (Figure 2C), a critical pathway known 
to be deregulated in invasive cancer [30, 31] and a key 
Figure 1: miR-200b-3p regulates epithelial to mesenchymal transition in triple negative breast cancer. (A) A cohort of 
ER+ (ZR75, MCF-7) and ER- (MDA-MB-157, MDA-MB-231, BT-549, Hs578t) breast cancer cell lines were tested by qPCR to determine 
basal miR-200b-3p expression. U6 was used for internal normalization and compared to the MCF-7 breast cancer cell line (designated as 1). 
(B) qPCR for stable expression of miR-200b-3p in the MDA-MB-231 cell line following transfection with the pLEmiR-tRFP-miR-vector 
or –pri-miR-200b expression plasmids. (C) Transwell migration assay of MDA-MB-231-vector and –miR-200b cell lines following 24 
hours. Fixed and stained membranes were visualized by microscopy for cell migration and graphs represent mean number of migrated cells 
per field of view. (D) qPCR for basal CDH1, ZEB1, and ZEB2 expression in the MDA-MB-231-vector cell line versus –miR-200b. Beta-
actin was used as loading control and compared to MDA-MB-231-vector cell line (designated as 1). For all experiments error bars represent 
SEM for n = 3, and significance denoted by *p < 0.05, **p < 0.01, ***p < 0.001.
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player in EMT [23]. Interestingly, classical EMT signaling 
events were not predicted to be regulated in our 200b cells 
by pathway analysis. Overall, pathway analysis of these 
up and down regulated genes indicates inhibition of the 
invasive phenotype of TNBC by miR-200b expression, 
through non-canonical signaling.
Analysis of the small RNA fraction revealed 
significant alteration in expression of 1363 transcripts, of 
which 503 were upregulated and 859 were downregulated 
(Figure 2D). Interestingly, only 15 miRNA were included 
in these significantly altered transcripts, including miR-
200b-3p (Table 1).
Figure 2: Overexpression of miR-200b-3p Induces Global Gene Expression Changes in the MDA-MB-231 Cell 
Line. (A) Heat map representation of global RNA expression changes in the MDA-MB-231-miR-200b cell line versus –vector. (B) and 
(C) represent pathways associated with genes that are significantly downregulated (B) or upregulated (C) in the MDA-MB-231-miR-200b 
cell line compared to –vector control. Pathway analysis was performed using QIAGEN’s Ingenuity® Pathway Analysis (IPA). (D) Heat map 
representation of global miRNA expression changes in the MDA-MB-23-miR-200b cell line versus –vector.
Table 1: microRNA with significantly altered expression in MDA-MB-231-miR-200b cells 
compared to vector control
miRNA Fold change Role in cancer Refs
103a-2 0.31 Not known
181b1 0.02 oncomiR [65]
1915 0.00005 Tumor suppressor, Targets Bcl-2 [66]
20a 38.49 oncomIR. miR-17-92 family [67]
200b 5750.37 Anti-migratory, anti-EMT [19, 50]
21 0.36 oncomiR [68]
221 0.15 oncomiR, enhanced invasion [69]
3074 0.23 Not known
33B 0.06 Regulation of metabolism and cell cycle [70, 71]
3618 3.00 Not known
3648 0.35 Not known
574 0.05 Not known
598 0.12 Associated with esophageal cancer [72]
663a 0.26 Not known
let7f1 4.30 Anti-invasive, anti-metastatic [73]
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RNA-sequencing indicates differential regulation 
of gene expression by miR-200b-3p and 
miR-200-5p
Since there was no observed significant change 
in ZEB1 or ZEB2 in our MDA-MB-231-miR-200b cell 
line, we next sought to determine if any alterations were 
made to the miR-200b-3p transcript. As miR-200b-3p was 
induced as a precursor miRNA, alterations to the 5’ end 
of the miRNA may have been induced during maturation. 
This would then account for the loss of ZEB targeting. 
Surprisingly, upon validation of miR-200b expression 
in our whole transcriptome analysis as observed in the 
Integrative Genomics Viewer (IGV), expression of both 
the mature miR-200b-3p (guide strand) and miR-200b-
5p (the star strand/passenger) was enhanced in MDA-
MB-231-miR-200b (Figure 3A). Additionally there was 
no observed loss of 5’ heterogeneity in either miRNA 
strand (Figure 3A). Recent reports have shown that 
miRNA processing can favor strand selection, with the 
star strand or passenger strand being expressed at equal or 
higher levels than the conventional guide strand [32, 33]. 
Additionally, isomiRs, a miRNA transcript that differs 
from the primary transcript by one or two nucleotides, 
exist and demonstrate altered expression between cellular 
systems [34–36]. Since our miR-200b construct was 
expressed as pri-miR-200b, we evaluated previously 
published deep sequencing data to determine if miR-
200b-5p can exist with physiologically relevant expression 
levels or if our enhanced miR-200b-5p expression was 
merely an artifact of enforced expression. As seen in 
miRBase, miR-200b-5p isomiRs are documented and can 
occur at physiologically relevant levels [37–40] and can be 
expressed at detectable levels (data not shown) [41–45]. 
qPCR validation for miR-200b-5p in our MDA-MB-231-
miR-200b over expressing cell line revealed a significant 
increase in miR-200b-5p expression levels (Figure 3B). To 
examine if miR-200b-5p has a significant role in TNBC, 
Figure 3: miR-200b-5p is Differentially Regulated between ER+ and Triple Negative Breast Cancer Subtypes.  
(A) Representative graphical analysis of reads for miR-200b-3p and miR-200b-5p expression in the MDA-MB-231-miR-200b cell line as 
viewed in Integrative Genomics Viewer (IGV). (B) qPCR for stable expression of miR-200b-3p in the MDA-MB-231 cell line following 
transfection with the pLEmiR-tRFP-miR-vector or –pri-miR-200b expression plasmids. U6 internal normalization and comparison to 
the MDA-MB-vector (designated as 1). (C) A cohort of ER+ (ZR75, MCF-7) and ER- (MDA-MB-157, MDA-MB-231, BT-549, Hs578t) 
breast cancer cell lines were extracted for qPCR to determine basal miR-200b-5p expression. Normalization was to U6 and the MCF-7 
breast cancer cell line designated as 1 for comparison of relative expression. For all experiments error bars represent SEM for n = 3, and 
significance expressed as *p < 0.05, ***p < 0.001.
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we then examined miR-200b-5p expression across a panel 
of breast cancer cell lines. Similar to the pattern observed 
in miR-200b-3p expression (Figure 1A), miR-200b-5p 
demonstrated substantially reduced expression in TNBC 
versus ER+/luminal cell lines (Figure 3C). Although 
the -5p strand by convention represents the previously 
designated star strand is generally thought to have low 
to no basal expression, the relative expression of miR-
200b-5p in the ER+ cell lines tested was at physiologically 
robust levels (similar to that of miR-200b-3p; Figure 1A).
Since miR-200b-3p and miR-200b-5p were both 
expressed in our MDA-MB-231-miR-200b cell line 
and expression of both -3p and -5p were observed at 
physiologically relevant and similar endogenous levels 
in ER+ breast cancer cell lines, we next sought to 
evaluate the preference for isomiR expression for both of 
these miRNAs in our deep sequencing analysis. Relative 
counts of expressed isomiRs for both miRNAs are 
shown in Table 2. Notably, miR-200b-3p demonstrates 
greater variance on the 3’ end than miR-200b-5p, and as 
Table 2: Prevalence of miR-200b-3p and miR-200b-5p IsomiRs in MDA-MB-231-miR-200b 
Cell Line
hsa-miR-200b-5p hsa-miR-200b-3p Count
CAUCUUACUGGGCAGCAUUGGA 64
CAUCUUCCUGGGCAGCAUUGGA 1
CACCUUACUGGGCAGCAUUGGA 1
CAUCUUACUGGGCAGCAUUG 3
CAUCUUACUGGGCAGCAUUU 1
CAUCUUACUGGGCAGCAUUGG 19
CAUCUUACUGGGCAGCAUUGU 2
CACCUUACUGGGCAGCAUUGG 1
CAUCUUACUGGGCAGCAUU 8
CAUCUUACUGGGCAGCAU 1
CAUCUUACUGGGCAGCAUUGGAU 11
CAUCUUACUGGGCAGCAUUGGAG 1
CAUCUUACUGGGCAGCAUUGGAA 1
CAUCUUACUGGGCAGCAUUGGAUU 17
CAUCUUACUGGGCAGCAUUGGAUA 4
CAUCUUACUGGGCAGCAUUGGGUA 1
   AUCUUACUGGGCAGCAUUGGA 1
   AUCUUACUGGGCAGCAUUG 1
   AUCUUACUGGGCAGCAUUGGAU 6
UAAUACUGCCUGGUAAUGAUGA 3
UAAUACGGCCUGGUAAUGAUGA 1
UAAUACUGCCUGGUAAUGACGA 1
UAAUACUGCCUGGUAAAGAUGA 1
UAAUACUGCCUGGUACUGAUGA 1
UAAUACUGCCUGGUGCUGAUGA 1
UGAUACUGCCUGGUAAUGAUGAC 4
UAAUACUGCCUGGUGAUGAUGAC 5
UAAUACUGCCUGGUAAUGAGGAC 2
(Continued )
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stated above, there were little alterations in the 5’ end of 
either miRNA.
To evaluate the effects of miR-200b-3p and miR-
200b-5p on gene expression we analyzed expression 
changes in genes predicted to have a seed site to either miR-
200b-3p or miR-200b-5p. Seed sites for miR-200b-3p and 
miR-200b-5p were generated using an in house algorithm, 
Seedfinder, to identify all 7-mer and 8-mer seeds throughout 
the human genome; from this data seed sites found in the 
3’UTR of transcripts were analyzed. As seen in Figure 4A, 
miR-200b-3p and miR-200b-5p significantly repressed 
predicted target genes similarly, with only a slight increase 
in the repression of miR-200b-5p targets. Unexpectedly, 
our deep sequencing analysis revealed that some miRNA 
targets were not repressed. Furthermore some predicted 
miR-200-5p and miR-200b-3p targets demonstrated 
significantly enhanced expression. Due to this, we next 
chose to evaluate alterations in the MDA-MB-231-miR-
200b transcriptome to better determine a mechanism for loss 
of targeting by miR-200b-3p/200b-5p in the MDA-MB-231 
cell line. Predicted targets were evaluated for alterations in 
mRNA 3’UTR architecture and mRNA isoform variance. 
Due to the large number of predicted targets that were not 
changed or increased in our MDA-MB-231-miR-200b cell 
line, genes demonstrating low basal levels of expression or 
those that did not contain an 8-mer miR-200b-3p/200b-5p 
seed site were not evaluated. Table 3 demonstrates the 
mRNAs that were predicted to be targeted by miR-200b-
3p or miR-200b-5p with increased expression levels 
and describes if alterations in mRNA 3’UTR or isoform 
expression was observed. Interestingly, many of the genes 
predicted to be targeted by miR-200b-3p or miR-200b-5p 
demonstrated loss of 3’UTR. Some EMT associated genes 
demonstrating loss of 3’UTR include DUSP1, ROCK2, 
DLC1, FZD3, AHR, and ELK4.
miR-200b-3p and miR-200b-5p synergize to 
target non-canonical EMT pathway
To gain greater insight into miR-200b induced 
alterations in gene expression, all predicted miR-200b-
3p and miR-200b-5p targets which were significantly 
down regulated in our deep sequencing analysis were 
analyzed through the use of IPA (Ingenuity® Systems, 
www.ingenuity.com). Top down regulated pathways for 
miR-200b-3p (Figure 4B) and miR-200b-5p (Figure 4C) 
included many overlapping pathways reported in our 
original pathway analysis of all significantly down 
regulated genes (Figure 2B). Interestingly, EMT signaling 
events were not predicted by pathway analysis of 
significantly down regulated predicted targets. Overall, 
given our biological data demonstrating an increase of 
the MET regulating gene, CDH1, and a loss of cellular 
migration in vitro, along with pathway analysis of 
transcriptome changes suggest that miR-200b-3p/200b-
5p act to inhibit the invasive phenotype of TNBC through 
non-canonical signaling. Of interest was the repeated 
evidence of inhibition of the RHO signaling pathway 
hsa-miR-200b-5p hsa-miR-200b-3p Count
UAAUACUGCCUGGUAAAGAUGAC 4
UAAUACUGCCUGGUAAGGAUGAC 8
UAAUACUGCCUGGUAACGAUGAC 2
UAAUACUGCCUGGUAGUGAUGAC 2
UAAUACUGCCUGGUAAUAAUGAC 1
UAAUACUGCCUGGUACUGAUGAC 1
UAAUACUGCCUGGUAAGGAUGACA 1
UAAUACUGCCUGGUAAGGAUGACC 1
UAAUACUGCCUGGUAGUGAUGACU 1
UAAUACGGCCUGGUAAUGAUGACU 1
   AAUACUGCCUGGUAUUCAUGACU 1
   AAUACUGCCUGGUAUUCAUGACU 1
UAAUACUGCCUGGUAAUGAAT 6
UAAUACUGCCUGGUAAUG 11
UAAUACUGCCUGGUAAU 17
Colored text indicates primary sequence for miR-200b-5p (red) and miR-200b-3p guide (blue). Black text represents
isomiR sequences with altered nucleotides indicated in bold/underlined print.
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evident by pathway analysis of down regulated target 
genes for both miR-200b-3p and miR-200b-5p.
To determine relevance of miR-200b-3p/200b-
5p targeting of the RHOGDI signaling pathway in the 
TNCB phenotype, we performed analysis of previously 
published patient tumor data freely available through 
The Cancer Genome Atlas (TCGA) in collaboration 
with the UCSC Cancer Browser [46–49]. The genes 
RHOGDI associated genes RHOA, LIMK1, CDC42, 
RAC1, ROCK2, ITGA2, ITGA1, PRKCA, PIP4K2A were 
analyzed. These genes were chosen based on predicted 
targets of miR-200b-3p/200b-5p which demonstrated 
significantly repressed expression in our deep sequencing 
data or based on relevance to RHOGDI pathway. Of 
interest PRKCA demonstrated significantly higher 
levels of expression in basal like tumors and is a miR-
200b-5p predicted target (Figure 5A). To better evaluate 
the differences between PRKCA and the triple negative 
Figure 4: miR-200b-3p and miR-200b-5p Display Synonymous Regulation Patterns of Target Pathways. Deep 
sequencing analysis for gene fold change and altered pathways in the MDA-MB-231-miR-200b cell line. (A) Graphical representation of 
observed fold change of genes which contain either a miR-200b-3p or miR-200b-5p seed site with significantly altered expression by deep 
sequencing. (B) and (C) represent top pathways predicted to be affected by genes which contain either a miR-200b-3p (B) or miR-200b-5p 
(C) seed site and were observed to be significantly down regulated. Pathways were determined through the use of IPA (Ingenuity® Systems, 
www.ingenuity.com).
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phenotype, qPCR was performed for PRKCA across 
ER+ and triple negative breast cancer cell lines. PRKCA 
demonstrated no significant change in expression levels 
between the two cohorts (Supplemental Figure 1). The 
relevance of interactions between PRKCA, miR-200b, 
and EMT has been recently evaluated and there is an 
emerging importance of this pathway in relation to EMT 
in TNBC [19, 50]. Importantly, we demonstrate that key 
components of the RHOGDI pathway demonstrate loss of 
3’UTR (DLC1, ROCK2) in the MDA-MB-231 cell line. 
This may emerge as an important factor for consideration 
when developing methods for intervention.
DISCUSSION
microRNAs are key regulators of breast cancer 
progression where alterations in their expression can give 
rise to EMT and metastasis. While conventional studies 
on miRNAs demonstrate alterations in miRNA expression 
correlating to an enhanced breast cancer phenotype, the 
utilization of deep sequencing adds greater depth to 
changes in miRNA expression. Recent evidence suggests 
that the miRNA is more complex than previously thought. 
A single miRNA transcript has the potential to give rise 
to multiple isomiRs which have differences in expression 
in both the guide and star strand. Here we demonstrate 
that the ectopic expression of the pri-miR-200b gives 
rise to both miR-200b-3p and miR-200b-5p in addition 
to altered isomiRs for each miRNA, where both miR-
200b-3p and miR-200b-5p demonstrated 3’heterogenity. 
In fact, the more prominent transcript of miR-200b-3p 
expressed in our MDA-MB-231 cell line is truncated 
at the 3’ end. The effects of miRNA 3’heterogenity on 
biological targeting and miRNA expression remain 
to be determined and warrant further investigation. 
Interestingly, while miR-200b-3p is expressed in isomiRs 
of variable length, there is greater consistency in the 
expression of the less-conventional miR-200b-5p isomiR. 
Table 3: Loss of 3’UTR in genes with miR-200b-3p and miR-200b-5p seed sites
miR-200b-3p miR-200b-5p
Target gene Expression 3′UTR Loss Fold Change Target gene Expression 3′UTR Loss Fold Change
ABI2 Unchanged No AHR Unchanged Yes
BAP1 Unchanged No ALG2 Unchanged Yes
CAST Unchanged Yes AQR Unchanged Yes
COX7C Increased Yes 1.33 (p < 0.01) BTBD1 Increased Yes 1.37 (p < 0.05)
CYTH3 Unchanged No CHSY1 Unchanged Yes
DLC1 Increased Yes 1.97 (p < 0.001) CPNE3 Increased Yes 1.27 (p < 0.05)
DOCK4 Unchanged Yes EPT1 Unchanged No
DUSP1 Increased Yes 3.89 (p < 0.001) FZD3 Increased Yes 1.94 (p < 0.001)
ELK4 Unchanged Yes HNRNPU Unchanged Yes
ELL2 Unchanged Yes KCTD12 Unchanged Yes
HS3ST1 Increased Yes 2.06 (p < 0.01) LAP3 Unchanged Yes
JUN Unchanged No NAMPT Unchanged Yes
KIF1B Unchanged Yes ORC2 Unchanged Yes
RNGTT Unchanged Yes PCMTD2 Unchanged Yes
ROCK2 Unchanged Yes PPRC1 Increased Yes 1.52 (p < 0.001)
RRP15 Unchanged Yes RAP2A Unchanged No
TRIM33 Unchanged Yes SDPR Unchanged Yes
UBE2B Unchanged Yes UBE3A Unchanged No
USP46 Unchanged Yes UHMK1 Unchanged No
WDR91 Unchanged No UHRF1BP1 Unchanged Yes
WIPF1 Unchanged Yes USP22 Unchanged Yes
ZMAT3 Increased Yes 1.44 (p < 0.05) WDFY3 Unchanged Yes
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Mechanisms for this may be due to differences in the 
proteins associated with miRNA biogenesis, such as the 
argonautes. There are four argounatue (AGO) proteins in 
humans AGO1–4 and evaluation of alterations in AGO1–
4 gene expression across breast cancer cell lines and 
tumor samples has shown that AGO2 is increased in ER- 
samples versus ER+ while there is no change in AGO1, 
AGO3, or AGO4 [51]. Additionally the AGO proteins 
select for miRNA isomiRs and this selection is based on 
changes in both 5’ and 3’ heterogeneity [52]. Evaluation 
of changes in AGO expression and the implications on 
interactions with tumor suppressive miRNAs such as the 
miR-200 family may give greater insight into differences 
in miRNA expression changes in TNBC. There were 
few alteration to the 5’ends of the miR-200b-3p and 
miR-200b-5p isomiRs. As the 5’end of the miRNA 
dictates the possible mRNA targets, this is important as it 
suggests that conventional mRNA targets of miR-200b-
3p and miR-200b-5p should be repressed. Despite intact 
seed sequence in our miRNAs, few predicted targets 
of both miR-200b-3p and miR-200b-5p are repressed 
in the MDA-MB-231-200b cell line. Further analysis 
of predicted targets of miR-200b-3p and miR-200b-5p 
demonstrated a loss of targeting due to shortening of 
3’UTR in the target mRNA. Actively proliferating cells 
and cancers demonstrate loss of 3’UTR through increased 
Figure 5: miR-200b-3p and miR-200b-5p Synergize to Target Non-canonical EMT Pathway in Triple Negative Breast 
Cancer Tumors. (A) Deep sequencing data of human breast cancer tumors was obtained from TCGA data portal and was analyzed 
for genes associated with the RHOGDI pathway (RHOA, LIMK1, CDC42, RAC1, ROCK2, ITGA2, ITGA1, PRKCA, PIP4K2A) with 
respect to the basal subtype. Heat map depicts high expression (red, +1) and low expression (green, –1). Platform analyzed was TCGA 
breast invasive carcinoma gene expression Illumina HiSeq, n = 1032. (B) Depiction of RHOGD1 pathway and co-repression of predicted 
miR-200b-3p and miR-200b-5p target genes.
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alternative polyadenylation (APA) [53, 54]. Shortening 
of the 3’UTR will result in loss of gene targeting by 
miRNAs as there are fewer seed sites present in the 
3’UTR. Pri-miR-200b transfection into the mesenchymal 
MDA-MB-231 cell line resulted in loss of repression 
of many miR-200b-3p and miR-200b-5p targets. This 
evaluation draws to light considerations that must be 
made when evaluating treatments for breast cancer. 
New predictions for therapies suggest the modulation of 
miRNAs and demonstrate increased miRNA expression 
following drug treatment [55]. However our study 
suggests that the mRNA transcriptome must also be 
evaluated for miRNA modulation to be effective. Loss 
of 3’UTR in TNBC may dampen the effect of miRNA 
intervention due to loss of available seed-sites. In 
conjunction with previous studies on the miR-200 family, 
we demonstrate loss of miR-200b-3p expression in the 
basal TNBC compared to ER+/epithelial cancer cell lines, 
in addition we expand on this by showing miR-200b-
5p is also equally reduced. In addition miR-200b-3p is 
unable to fully repress ZEB1 and ZEB2 suggesting that 
basal/TNBC have escaped the canonical ZEB/miR-200b 
feedback loop. Despite the lack of a large effect on ZEB1 
and ZEB2, we demonstrate CDH1 repression and loss of 
invasive capacity in MDA-MB-231 –miR-200b cells. We 
suggest that this is through the fidelity in the targeting 
of miR-200b-3p and miR-200b-5p where both miRNAs 
target the RHOGDI signaling pathway. Non-canonical 
targeting of the RHO pathway by miR-200b-3p has also 
been recently demonstrated [14]. We expanded on these 
findings by demonstrating alterations in the RHOGDI 
signaling pathway correlate with a TNBC phenotype in 
clinical samples.
miR-200b-3p can directly target the 3’UTR of 
PRKCA and inhibition of metastasis of TNBC, supporting 
our findings [19]. Additionally, PRKCA can activate 
RHOGDI, which in turn activates RHOA, illustrating 
the importance of PRKCA and RHO signaling in the 
progression and metastasis of TNBC. Our data indicates 
that miR-200b-5p may also directly target PRKCA, 
while miR-200b-3p is predicted to target RHOA in 
addition to PRKCA. Figure 5B illustrates the predicted 
miR-200b-3p and miR-200b-5p targeting of the RHO 
signaling pathway at multiple points, with down regulated 
genes indicated in blue. The importance of these findings 
demonstrates novel mechanisms for the intervention of 
TNBC.
MATERIALS AND METHODS
Cells and reagents
MCF-7, ZR75, MDA-MB-157, MDA-MB-231, 
Hs578t, and BT-549 human breast cancer cell lines 
were acquired from American Type Culture Collection 
(Manassas, VA). Liquid nitrogen stocks were made upon 
receipt and maintained until the start of study. Morphology 
and doubling times were also recorded regularly to ensure 
maintenance of phenotype for all cell lines. Cells were 
used for no more than 6 months after being thawed. Cells 
were maintained as previously described [56]. Briefly cells 
were maintained at 37°, 5% CO2 in DMEM (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine 
serum (Hyclone, Salt Lake City, UT, USA) and 1% 
penicillin/streptomycin (Invitrogen).
RNA extraction and quantitative
Real Time RT-PCR MDA-MB-231-vector and 
MDA-MB-miR-200b cells were harvested for total RNA 
extraction using Qiagen RNeasy RNA purification system 
or for microRNA miRNeasy purification system per 
manufacturer’s protocol (Qiagen, Valencia, CA). Quantity 
and quality of the RNA and miRNA were determined by 
absorbance at 260 and 280 nm using the NanoDrop ND-
1000. 2ug of total RNA was reverse-transcribed using the 
iScript kit (BioRad Laboratories, Hercules, CA) and qPCR 
was performed using SYBR-green (Bio-Rad Laboratories, 
Hercules, CA). β-Actin, CDH1, PRKCA, ZEB1, and 
ZEB2 amplified n > 3. miRNA was reverse–transcribed 
using the SABiosciences RT2 miRNA first strand kit 
(Qiagen, Valencia, CA) and qPCR was performed using 
SABiosciences SYBR green, miR-200b-3p, miR-200b-
5p, and U6 primer purchased from Qiagen (Valencia, 
CA). Data was analyzed by comparing relative target 
gene expression to β-actin for mRNA and U6 for miRNA. 
Relative gene expression was analyzed using 2-ΔΔCt 
method [57].
Transfection of cell lines
pri-miR-200b and empty vector pLemir plasmids 
were purchased from Open Biosystems (Lafayette, CO). 
MDA-MB-231 cell line was transfected through lenti-viral 
transfection as previously described [58] and retrovirus 
packing was performed following the manufacturer’s 
instructions (Thermo ScientificBio, Pittsburgh PA). 
The following day cells were treated with 300 ng/ml 
puromycin. Cells were maintained in 10% DMEM and 
treated with 300 ng/ml puromycin every two days for 2 
weeks. Colonies were pooled and verification of mature 
miR-200b-3p and later -5p overexpression was confirmed 
using qPCR for mature miR-200b-3p and -5p. Stable pools 
were maintained in 10% DMEM as described above.
RNA-sequencing analysis
Read preparation, repeat masking, and read mapping 
were conducted as we have previously published [59]. In 
addition to our published methods, reads were mapped 
using custom perl scripts. A read is considered mapped 
to a gene if all but 2 (or fewer) bases of the read map to 
annotated exons of a gene (though the exon boundaries 
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do not have to correspond to an identified isoform). 
After mapping the collapsed read set was expanded back 
to its original size both so that the disposition for every 
read could be accounted for and to facilitate the use of 
other tools expecting a standard SAM formatted dataset. 
Counts were determined from the expanded set of reads. 
Typically a read was mapped to one and only one annotated 
element in the human genome. While unlikely due to 
the strandedness of the reads, a read that was mapped to 
multiple genes in the genome incremented the count for 
each gene. Reads that map to multiple locations were 
marked as ambiguous and were not counted. Reads that 
were marked as repetitive (due to RepeatMasker) were 
used only if they could be mapped to a unique location in 
the genome.
Differential gene expression was determined using 
the edgeR software [60] [version 2.6.0] by supplying 
it the raw gene counts. Dispersion was estimated using 
both the estimatecommonDisp and estimateTagwiseDisp 
methods [61, 62]. A prior n value = 10 was used for 
running estimateTagwiseDisp. The exactTest method was 
run using default parameters allowing edgeR to decide 
which dispersions to use [63]. Pathway analysis was 
performed using GeneGo Metacore (Thomson Reuters). 
The Enrichment Analysis Workflow was performed using 
the gene list, fold-change and p-value scores generated 
by edgeR. A threshold p-value of < 0.05, and threshold 
fold-change < 0.5 was set when performing the analysis 
in GeneGo.
Data derived from RNA sequencing were analyzed 
for pathway analysis through the use of QIAGEN’s 
Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood 
City, www.qiagen.com/ingenuity).
Transwell migration assay
Migration assays were performed following the 
manufacturer’s instructions (BD Biosciences, San Jose, 
CA) and as previously published [64]. Cells were seeded 
at a density of 2.5 × 104 cells per well in serum free media. 
DMEM supplemented with 10% FBS (10%) was used as 
a chemo-attractant. DMEM without FBS (0%) served as a 
negative control. After 24 hours, migrated cells were fixed 
to the membranes and stained. Migrated cells visualized by 
microscopy, and data is represented as number of migrated 
cells per field of view ± SEM for triplicate experiments.
Breast cancer data sources
Breast cancer gene expression deep sequencing 
was viewed through the University California Santa 
Cruz (UCSC) Cancer Genomics Browser and compiled 
by The Cancer Genome Atlas (TCGA) research network 
[46–49]. The TCGA dataset used was the breast invasive 
carcinoma and it was analyzed for gene expression 
aligned through the Illumina HiSeq system total tumor 
samples were n = 1032.
Statistical analysis
Statistical Analysis was performed using Graph 
Pad Prism 5. Student’s t-test was used to determine p 
values and statistically significant values had a p values 
of < 0.05.
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